Editas Medicine, Inc. (EDIT)

In the past six months, Editas Medicine's stock experienced several notable events. The company announced its Q3 2025 financial results and business updates on November 10, 2025, highlighting progress with EDIT-401 and an extended cash runway into the third quarter of 2027. Preclinical data for EDIT-401 was presented in October and November 2025, demonstrating significant LDL cholesterol reduction in non-human primates. On March 9, 2026, the company reported its Q4 and full-year 2025 results, including continued advancement of EDIT-401. On March 27, 2026, the U.S. Patent and Trademark Office reaffirmed its decision in favor of the Broad Institute regarding CRISPR/Cas9 interference. The stock has shown significant volatility, with shares surging by 80% over the past year but experiencing a loss of over 90% of its market value in the last five years. As of April 8, 2026, the share price was $2.76, representing a 140.00% increase over the price on April 9, 2025. Editas Medicine has received a consensus rating of "Moderate Buy" from analysts.

Editas Medicine, Inc. does not experience traditional demand seasonality for its products and services. The demand for its experimental medicines is driven by the progression of clinical trials, regulatory approvals, and the medical need for transformative treatments for specific genetic diseases. The company's revenue is primarily derived from collaboration agreements and equity financing, rather than direct product sales.

Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing transformative genomic medicines using CRISPR gene editing technology, operating within the Healthcare sector and Biotechnology industry. The company leverages CRISPR/Cas9 and CRISPR/Cas12a systems to correct disease-causing mutations. Its pipeline includes experimental medicines like EDIT-301 for sickle cell disease and beta-thalassemia. EDIT-101, a CRISPR-based gene therapy for Leber congenital amaurosis 10 (LCA10), was halted due to the inability to secure a financially robust partner. EDIT-103 was abandoned. EDIT-401, designed to reduce LDL cholesterol levels, is expected to have an IND or CTA submission by mid-2026, with a clinical trial planned for later in 2026 and early human proof-of-concept data targeted by year-end 2026. The company is also researching in vivo gene editing medicines for other tissue types and advancing cellular therapy assets through partnerships for oncology.

Editas Medicine, Inc. is headquartered in Cambridge, Massachusetts, and has facilities in Boulder, Colorado, United States. Its intellectual property extends across various international jurisdictions, including the U.S., Europe, Japan, China, and Australia.

Editas Medicine's brand reputation has been influenced by scientific advancements, clinical program updates, and financial performance. Positive influences include the CRISPR patent reaffirmation and promising preclinical data for EDIT-401. The acceptance of the first IND/CTA for the CD19 HD Allo CAR T program as part of its collaboration with Bristol Myers Squibb also contributed positively. Challenges include the halting of EDIT-101 development, R&D challenges, commercialization hurdles, significant stock volatility, financial losses, and slow clinical progress.

The ownership structure of Editas Medicine is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 51.02% to 71.90% of the company's stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Individual investors hold a significant portion, approximately 55%, of the company's shares. Insiders own under 1% to 33.67% of Editas Medicine, Inc., with Third Rock Ventures III LP being a significant individual shareholder.